MenAfriVac heat-stable vaccine (2010)
The Serum Institute of India and PATH developed MenAfriVac, a meningitis A vaccine priced near 50 cents a dose and formulated to tolerate temperatures of up to 40°C for days. It was the first vaccine designed for use across Africa's meningitis belt without a strict cold chain.
Mass campaigns vaccinated hundreds of millions of people in West and Central Africa, cutting meningitis A cases sharply.
MenAfriVac proved that temperature-tolerant biological products are achievable, becoming a template for cheaper, easier-to-distribute vaccines.
BoSS teams use the same toolset — formulation, drying, and stabilization chemistry — to push far beyond vaccines and stabilize living therapeutic cells at room temperature.
